| 1 |
34410044 | Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel. | 2022 Jan |
2 |
| 2 |
32338045 | Influences of Smoking Status on Effectiveness of Cytochrome P450 Enzyme System Metabolized Medications in Reducing In-Hospital Death in 14 658 Patients With Acute Myocardial Infarction: Data From CPACS-3 Study. | 2020 Sep |
1 |
| 3 |
30936195 | Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice. | 2019 Apr |
2 |
| 4 |
30998396 | Clopidogrel Pharmacogenetics. | 2019 Apr |
2 |
| 5 |
31418753 | Smoking and cardiovascular diseases: paradox greater than expected? | 2019 Oct 30 |
2 |
| 6 |
27637911 | Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2. | 2018 Jan |
2 |
| 7 |
29449127 | Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel. | 2018 Jun |
3 |
| 8 |
29496531 | Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. | 2018 Sep |
2 |
| 9 |
29858511 | Cytochrome P450 genotype-guided drug therapies: An update on current states. | 2018 Oct |
2 |
| 10 |
26633836 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. | 2016 Mar |
2 |
| 11 |
26961113 | Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. | 2016 Oct 1 |
1 |
| 12 |
27239927 | [The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism]. | 2016 |
1 |
| 13 |
25666703 | New insight into the mechanisms of gastroduodenal injury induced by nonsteroidal anti-inflammatory drugs: practical implications. | 2015 |
1 |
| 14 |
26220948 | Human Liver Cytochrome P450 Enzymes and Microsomal Thiol Methyltransferase Are Involved in the Stereoselective Formation and Methylation of the Pharmacologically Active Metabolite of Clopidogrel. | 2015 Oct |
1 |
| 15 |
26639695 | Pharmacogenetic testing in population of South Ural. | 2015 |
3 |
| 16 |
24500235 | Prasugrel and ticagrelor: is there a winner? | 2014 Jan |
2 |
| 17 |
24762860 | Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. | 2014 Jun |
4 |
| 18 |
24803100 | Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study. | 2014 Nov |
2 |
| 19 |
23149816 | Clinical impact of genetically determined platelet reactivity. | 2013 Jun |
3 |
| 20 |
23480885 | [Genetic variability in the efficacy of clopidogrel]. | 2013 Mar 11 |
2 |
| 21 |
23770199 | Hepatocellular toxicity of clopidogrel: mechanisms and risk factors. | 2013 Dec |
2 |
| 22 |
23903277 | [Statin and clopidogrel pharmacological interaction]. | 2013 Sep |
4 |
| 23 |
24378836 | Genetic and nongenetic factors influencing the response to clopidogrel. | 2013 Dec |
4 |
| 24 |
24378837 | Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel. | 2013 Dec |
4 |
| 25 |
22568693 | Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. | 2012 Jul 1 |
4 |
| 26 |
22589111 | Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis. | 2012 Apr |
1 |
| 27 |
20845077 | Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. | 2011 Mar |
2 |
| 28 |
20980920 | The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. | 2011 Jan |
2 |
| 29 |
21251580 | Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. | 2011 Jan 25 |
1 |
| 30 |
21352268 | Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? | 2011 Oct |
3 |
| 31 |
21392639 | Clopidogrel-drug interactions. | 2011 Mar 15 |
5 |
| 32 |
21546883 | The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. | 2011 |
2 |
| 33 |
21771377 | [Interaction between clopidogrel and proton pump inhibitors]. | 2011 |
2 |
| 34 |
21826477 | Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance. | 2011 Oct |
1 |
| 35 |
19904241 | Proton pump inhibitor and clopidogrel interaction: fact or fiction? | 2010 Jan |
3 |
| 36 |
19919843 | Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. | 2010 Feb |
5 |
| 37 |
20180610 | Genetic causes of clopidogrel nonresponsiveness: which ones really count? | 2010 Mar |
2 |
| 38 |
20735423 | Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. | 2010 Sep |
3 |
| 39 |
19106084 | Cytochrome p-450 polymorphisms and response to clopidogrel. | 2009 Jan 22 |
3 |
| 40 |
19337788 | Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. | 2009 Mar |
2 |
| 41 |
19414633 | Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. | 2009 May 19 |
2 |
| 42 |
19576320 | Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. | 2009 Jul 1 |
4 |
| 43 |
18482659 | Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. | 2008 May 20 |
4 |
| 44 |
18687246 | The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. | 2008 Aug 12 |
2 |
| 45 |
17900275 | Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. | 2007 Dec |
2 |
| 46 |
16772608 | Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. | 2006 Oct 1 |
6 |
| 47 |
16011979 | The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. | 2005 Aug |
1 |
| 48 |
14522569 | Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. | 2003 Oct |
3 |